

Supplementary Table S1. Baseline demographic and clinical features of RA and OA.

Characteristic	RA (n=18)	OA (n=13)
Demographic		
Age, median (IQR)	59 (51 to 66)	61 (53 to 65)
Female (n%)	10 (55.6)	7 (53.8)
Disease status		
Disease duration, median (IQR)	38 (12 to 120)	72 (24 to 120)
CRP (mg/dl)	7.4 (2.1 to 9.1)	0.4 (0.2 to 0.9)
ESR (mm/h)	69 (53 to 107)	18 (11 to 29)
RF (n%)	17 (94.4)	—
Anti-CCP-positive, n (%)	15 (83.3)	—
DAS28, median (IQR)	5.8 (4.8 to 6.4)	—
Previous medications		
Corticosteroids (n%)	7 (38.9)	—
Methotrexate (n%)	8 (44.4)	—
Leflunomide (n%)	5 (27.8)	—
Sulfasalazine (n%)	2 (11.1)	—
Hydroxychloroquine (n%)	3 (16.7)	—
Etanercept (n%)	4 (22.2)	—

CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; Anti-CCP: anti-cyclic citrullinated peptide antibodies; DAS28: disease activity score 28-joint assessment; —: not applicable.

Supplementary Table S2. Primers for quantitative real-time PCR.

Molecule	Sense primer (5'-3')	Antisense primer (5'-3')
TRPC1	TTAGAGCTGGACTGGCCAAA	ATGCACATTGTGTTCTGCAA
TRPC3	CTTACCTCTCATTTGTCCAGCG	CCAGCACACCCACTACAAAG
TRPC4	TCACCTCAGCCGAAGATTG	ATCCTTAGAGGGATGCGGTC
TRPC5	GCGGTCTCTGTACGGTGAGTA	AAAAACCACTTGGCTCAGGA
TRPC6	GGTGAGCCAGTCTGTTGTCA	TATCTGCTCATGGACTCGGA
TRPC7	CACGCCCCACTACAAAATCCT	TCAGCAACGAGTTAGCCAGA
TNF- α	GCCAGAGGGCTGATTAGAGA	TCAGCCTCTTCTCCTTCCTG
IL-6	CCAGGAGAAGATTCCAAAGATG	GGAAGGTTTCAGGTTGTTTCTG
MMP-13	GCTGCCTTCCTCTTCTTGA	TGCTGCATTCTCCTTCAGGA
GAPDH	GAAGGTCGGAGTCAACGG	GGAAGATGGTGATGGGATT

TRPC: transient receptor potential canonical; MMP: matrix metalloproteinase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase.